Abstract:Aim: To compare the effect, safety and tolerance of citalopram and venlafaxine for depressive disorder. Methods: The patients, who were tre ated at the out-patient clinic or hospitalization, Center of Mental Health, Renmin Hospital, Wuhan University from October 2003 to October 2004,were divided randomly into 2 groups. Those in the citalopram group with 32 cases were treated with 20-40 mg citalopram per day; Those in the venlafaxine group with 34 cases were treated with 150-225 mg venlafaxine per day for six weeks. Before treatment and at the end of 1st, 2nd, 4th and 6th of treatment, they were assessed by the Hamilton Depression Rating Scale (totally 17 items, the 5 grades score of 0-4 points, 0 point for without this symptom, 4 points for severe), Clinical global impression scale (CGIS) (8 grade score of 0-7 points, 0 point for without disease, 7 points for severe) and Treatment Emergent Symptom Scale (TESS) (5 grade score of 0-4 points, 0 point for without this symptom, 4 points for severe). The effects were assessed by the Hamilton depression rating scale to perform division of reducing score rate, ≥ 25% for effective, ≥ 50% for significant effect, ≥ 75% for recovery. The CGIS was used to divide, ≤ 2 for effective, ≤ 1 for recovery. Results: One in the citalopram group was withdrew at the end of the 4th week; Two in the venlafaxine group, one was at the end of the 2nd week, the other was moved back because of bad reaction. Totally 63 cases were finished the 6-week observation, 31 cases in the citalopram group, 32 cases in the venlafaxine group. (1) Comparison of the scores of Hamilton depression rating scale and CGIS before and after the treatment in the two groups: The comparison of reducing score value of the general score of Hamilton depression rating scale and score of CGIS after treatment in two groups showed that at the end of 2nd and 4th week were bigger in the venlafaxine group than that in the citalopram group (17.47±5.26, 24.33± 6.32; 12.13±5.87, 19.73±6.24; 3.73±1.03, 4.66±0.89; 3.26±1.03, 4.06 ±0.79, P < 0.01, P < 0.05). (2) Comparison of effects in the two groups: The reducing score rate of general score of Hamilton depression rating scale at the end of the 6th week showed that the efficiency, significant effect and recovery rate in the citalopram group and the venlafaxine group was similar (94%, 94%; 68%, 72%; 13%, 25%). The efficiency and recovery rate in the citalopram group by the CGIS were similar (81 %, 84%; 42%, 53%). (3) Comparison of bad reaction incidence: It was lower in the citalopram group than that in the venlafaxine group (13%, 47%, P=0.005). Conclusion: The citalopram and venlafaxine have similar effects on the treatment of depressive disorder, and the response of the venlafaxine occurres earlier than that of the citalopram. They all have good safety, and there are fewer and slighter side effects of citalopram compared with the venlafaxine.

Clinical effects of venlafaxine in treatment of depressive disorder associated with anxiety and its impact factors

Treatment of Depressive Outpatient with Venlafaxine:An Open Clinical Trial

Venlafaxine vs clomipramine in treating major depression associated with anxiety

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Expert consensus for clinical appliance of venlafaxine controlled release formulation

Research on the Effect of Escitalopram and Venlafaxine in the Treatment of Patients with Initial Diagnosis of Major Depressive Disorder

A comparison study of sertraline,venlafxin and alprazolam in treatment of generalized anxiety disorder

Venlafaxine in treating 62 patients with depression: a multicenter open trial

The Clinical Study of Venlafaxine Slow Release Tablets for Treatment of Generalized Anxiety Disorder

A Clinical Study of Venlafaxine in the Treatment of Anxiety in Elderly Hypertensive Patients with Anxiety

Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial

Effects of Venlafaxine on the Sleep of Depressed Patients

Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms: An open‐labeled randomized control trial

Omega-3 Polyunsaturated Fatty Acids Supplementation Alleviate Anxiety Rather Than Depressive Symptoms Among First-Diagnosed, Drug-Naive Major Depressive Disorder Patients: A Randomized Clinical Trial

Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear.

Comparison of citalopram and venlafaxine for depressive disoder

Efficacy and Safety of Venlafaxine XR in Aged Patients with Major Depressive Disorder and Hypertension: an Open-label Study

Omega-3 Polyunsaturated Fatty Acids Supplementation Alleviate Anxiety Rather Than Depressive Symptoms Among First-Diagnosed, Drug-Naïve Major Depressive Disorder Patients: A Randomized Clinical Trial

Venlafaxine Inhibits the Upregulation of Plasma Tumor Necrosis Factor-Alpha (Tnf-Α) in the Chinese Patients with Major Depressive Disorder: A Prospective Longitudinal Study

Changes of inflammatory cytokines in patients with major depressive disorder before and after venlafaxine treatment

A Randomized and Double-Blind Clinical Trial of Venlafaxine Hydrochloride Sustained Release Capsules for Treating Juvenile Depression